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Our Vision and Priorities 
 
The National Center on Birth Defects and Developmental Disabilities (NCBDDD) works to advance the health 
and well-being of our nation’s most vulnerable populations.  Our focus on women, children, people with a 
range of disabilities and complex disabling conditions positions us as a resource within public health that is 
unique and vital.     
 
As we approach our ten year anniversary, a reflection on what we have accomplished and what we plan to 
achieve over the next five years is necessary.  This plan describes our vision for the upcoming years and our 
commitment to achieve important health outcomes during that period. 
 
This plan is intended to help guide our own work, but we have also used its creation as a tool to engage our 
partners and to solicit their input, expertise and commitment to move our collective efforts forward in 
meaningful and measurable ways. 
 
As we have created this plan, we have made the following assumptions: 
 
 Funding for current programs and activities will not increase substantially in the next three years given 
the current economic environment 
 
 Staffing levels within the center will remain relatively stable 
 
 Evolving trends within government and the private sector have important implications for our work   
 
 Opportunities to retool and reframe current programs are based on evidence-based information 
 
In a few instances, we have proposed activities and outcomes that will require resources beyond what is 
currently available.  However, we have weighed these circumstances in light of disease burden, clear 









Note:  Throughout this plan, various acronyms and abbreviations are used.  Please refer to Appendix I for a 





Our Background and History 
 
Established by the Children’s Health Act of 2000, CDC’s National Center on Birth Defects and Developmental 
Disabilities (NCBDDD) is currently organized into three divisions:  Birth Defects and Developmental Disabilities 
(DBDDD), Blood Disorders (DBD), and Human Development and Disability (DHDD).  Congress mandated the 
creation of the Center in response to strong advocacy efforts by external organizations whose view was that 
children’s health issues were not being adequately addressed by CDC.  Prior to formation of NCBDDD, CDC 
conducted an extensive internal assessment.  This assessment focused on existing maternal-child health 
programs and it made recommendations about critical functions, programs and structure.  The initial structure 
selected was the least disruptive to the Agency while also fulfilling the congressional mandate.  It included the 
activities of two of the current divisions:  Human Development and Disability and Birth Defects and 
Developmental Disabilities.  It was not until 2004 that the Division of Blood Disorders was transferred to the 
Center from the National Center for Infectious Diseases.  The rationale for moving Blood Disorders to NCBDDD 
was based upon the fact that the Center was already working on a number of chronic disability conditions with 
a strong genetic component. 
 
Clearly, the Center’s name does not accurately capture the breadth of our work.  For example, though each 
division has a focus on children, as we have gained a deeper understanding of our populations and as 
programs have matured, we come to realize that our perspective must be one of a life course approach.   In 
addition, as a Center, we consider health in the context in which people live and value health equity and 
inclusion for all groups and individuals. 
 
Similarly, our work with individual disorders is leading us to adopt a common approach in which we are 
building a public health framework that promotes quality of life for all rather than approaching health issues 
disorder by disorder.  In this way, we are working to build a model for a whole array of disabling conditions.  
Nevertheless, we recognize that many of the conditions that we address do not easily lend themselves to a 
“one size fits all” approach.  Both advocates and experts alike push for programs tailored to address the 
special needs of individuals with relatively rare conditions.  Our challenge is to balance this desire with 
economic realities.   The economic and long-term societal costs of rare disorders are substantial.  For example, 
in the United States, 20,000 people have hemophilia, yet the annual healthcare cost for them is $3 billion.  
Sickle Cell Disease affects 100,000 people in the U.S. at an annual cost of $1 billion. 
 
Our rationale for focusing on a life course approach is illustrated by the dilemma encountered by many people 
with disabilities (PWD).  As they lead ever more robust and longer lives through the advent of health and 
environmental advances, transition issues from one life stage to another become increasingly more important.  
For example, children with chronic conditions/disabilities like Sickle Cell Disease, congenital heart defects or 
spina bifida have historically been treated by pediatricians, but with ever-increasing life spans, adolescents 
and young adults are transitioning from the pediatric to the adult healthcare system.  Adult healthcare 
providers may not have the training, specialty knowledge or equipment to adequately address the needs of 
these individuals.  Therefore, the issue of transition from one provider type, practice setting or specialty 
facility is important in terms of long-term health outcomes for these populations.  Similar circumstances occur 
for individuals with fetal alcohol spectrum disorders and autism spectrum disorders.  In order to maximize 
their long-term health, we must develop and implement strategies to fundamentally improve these transitions 




In addition to this example, a few examples of each division’s activities by life course are also provided: 
 
Examples of NCBDDD Activities by Life Course 




Youth & young  
adulthood 
Adulthood 
DBDDD Research on the 
fetal effects of 
medications used 
during pregnancy  
Surveillance on the 
prevalence of birth 
defects  and 
developmental 
disabilities  
Long-term follow up of 
children with birth 
defects including spina 
bifida, congenital heart 
disease and Down 
Syndrome 
 







and referral for 
hemoglobinopathies  
Treatment centers 
focusing on healthcare 
quality issues of people 
with hemophilia 
Chronic disease risk 
factor reduction 
efforts for persons 
with blood disorders 
DHDD  Early identification 




and follow-up of 
adolescents with spina 
bifida, muscular 
dystrophy, ADHD and 
other disabling 
conditions 
Assess health status 
and risks of persons 
with disabilities; 
promote health care 
access and healthy 
lifestyles  
 
The Division of Birth Defects and Developmental Disabilities focuses on surveillance, public health research 
and primary prevention of birth defects and developmental disabilities.  The Division of Human Development 
and Disability’s work focuses on secondary prevention with a strong emphasis on quality of life issues for 
persons with disabilities.  The Division of Blood Disorders’ focus is on primary and secondary prevention with a 
strong educational component for adults of reproductive age, providers and patients with blood disorders. 
 
Our Partners and Constituents 
 
NCBDDD works collaboratively across federal agencies and other partner organizations to leverage work and 
services being carried out by the Center and our grantees.  For example, we work closely with HRSA’s Title V 
MCH block grant recipients, organizations funded through Department of Education programs, developmental 
disabilities councils, pediatricians, hematologists, and a variety of disability-oriented organizations.  Each of 
these groups amplify the work of NCBDDD by using our science and programs to inform and guide their work.   
 
A strong relationship with other federal agencies, including NIH, HRSA, and SAMHSA has evolved over the past 
40 years.  NCBDDD works closely with several of NIH’s Institutes, including NICHD, NIMH, NINDS, NIAAA and 
NHLBI.  In addition, we work with state health departments, non-governmental organizations and specialty 
organizations.  Our unique contribution to these relationships is the public health perspective – including the 
provision of data from population-based surveillance, the focus of our research on major preventable risk 
factors, and the rapid translation of research findings to prevention programs.  
 
Though some of our activities are designed to address the needs of vulnerable individuals, we clearly 
recognize our mandate to address the needs of vulnerable populations.  For example, in the area of 
emergency preparedness, our extensive knowledge of these vulnerable groups and their specific needs in an 
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emergency such as the influenza pandemic is a high priority area for our work.  We focus on policies that 
address those needs and work to ensure that existing programs consider the unique requirements of these 
populations.  As a Center, our philosophy is consistent with Hubert Humphrey’s famous quotation: 
 
“It was once said that the moral test of the government  
is how that government treats those who are in the dawn of life, the children;  
those who are in the twilight of life, the elderly; 
and those who are in the shadows of life, the sick, the needy and the handicapped.”     
 
Our Mandates and Authorities 
 
In addition to operating under various types of authorities (general, specific and shared) NCBDDD receives 
Congressional committee language annually that specifies Congress’ intent regarding how funds are to be 
expended.  For example, some of the specific authorities for the center direct the Center to work on particular 
programmatic activities, including Fetal Alcohol Syndrome, folic acid, and Tourette’s Syndrome to name a few.  
In some cases, authorities for a particular area of work may reside in specific and shared authorities.  This is 
the case with autism.   
 
In general, annually each CDC Center receives language after the passage of appropriations law, and NCBDDD 
leaders work closely with staff in CDC’s OD and in the Financial Management Office to ensure that the Center 
is responsive to Congress and compliant with these mandates and authorities.  A list of the Center’s general, 
specific and shared authorities are provided in Appendix II.    
 
Our Public Health Approach, Responsibility to Our Constituents 
 
As the Center begins its second decade, we thought an in-depth reflection of what we have accomplished, 
how we have operated, and what we want to accomplish in the next few years was in order.  This strategic 
planning process has allowed us to accomplish this work, and most importantly, to identify promising new 
areas ripe for active engagement.   In creating this plan, we identified our priorities by focusing on issues that 
share these characteristics: 
 
1. The magnitude of the problem is known and significant. 
2. Opportunities for prevention, intervention and improvement are present. 
3. Several conditions can be improved based on evidence-based interventions and strategies. 
4. Disparity reduction/amelioration is a central aspect of what we work to accomplish. 
5. The priorities are reinforced or supported by CDC-wide priorities, and clearly fit within our Center’s 
mandate. 
6. The priorities build on previous work or known scientific evidence. 
Center leaders led the strategic planning process, and at key stages of the work subject matter experts from 
throughout the Center were brought into discussions.   Once the plan was drafted, a thorough vetting process 
with internal staff and key partners was undertaken.  Input into the draft plan was actively sought and each 
recommendation was tracked, considered, and in almost every case included in this version of the plan.   
 
Subsequent reviews of the plan will be conducted within (and throughout) CDC, and implementation plans for 




Specifically, our strategic planning discussions confirmed that, in carrying out our work, NCBDDD strives to: 
 
 Characterize the problem, incidence, prevalence, and distribution of our Center’s priority health 
conditions to inform public health research, priority setting and program monitoring; 
 Conduct  epidemiological research to understand the major modifiable risk factors in order to develop 
intervention/prevention programs and policies; and 
 Develop, evaluate and disseminate effective programs and policies for adoption by global, national, 
state and local organizations. 
 
Success in these population-based activities will result in: 
 Prevention of birth defects and developmental disabilities; 
 Health promotion and inclusion of people with disabilities; 
 Prevention  of chronic disease and subsequent mortality in people with our targeted conditions; 
 Effective population level management of a number of existing conditions including blood disorders; 
and, 
 Preparedness for disasters and other potential catastrophic health events. 
 
With these perspectives in mind, the Center’s three priorities are to: 
 
1.  Prevent major birth defects attributable to maternal risk factors. 
 
2. Prevent death and disability due to deep vein thrombosis (DVT) and pulmonary embolus (PE).   
 
3. Reduce disparities in obesity and other health indicators in children, youth and adults with disabilities. 
 
Relationship between Center Priorities and Relevant Healthy People 2020 Goals 
 
Center Priority 1:  Prevent major birth defects attributable to maternal risk factors encompasses several 
Healthy People 2020 goals.  These include: 
 
MICH-1.6 Infant deaths related to all birth defects 
Baseline: 1.4 infant deaths per 1,000 live births were attributed to birth defects (all birth defects) in 2006  
Target: 1.3 infant deaths per 1,000 live births 
Target-Setting 
Method: 
10 percent improvement 
Data Source: National Vital Statistics System (NVSS), CDC, NCHS 
 
MICH-1.7  Infant deaths related to birth defects (congenital heart defects) 
Baseline: 0.38 infant deaths per 1,000 live births were attributed to congenital heart and vascular defects in 2006  





10 percent improvement 
Data Source: National Vital Statistics System (NVSS), CDC, NCHS 
 
MICH-11.1  Alcohol 
Baseline: 89.4 percent of pregnant females aged 15 to 44 years reported abstaining from alcohol in the past 30 days in 2007–
08  
Target: 98.3 percent  
Target-Setting 
Method: 
10 percent improvement 
Data Source: National Survey on Drug Use and Health (NSDUH), SAMHSA 
Baseline: 95.0 percent of pregnant females aged 15 to 44 years reported abstaining from binge drinking during the past 30 
days in 2007–08  




Data Source: National Survey on Drug Use and Health (NSDUH), SAMHSA 
 
MICH-15  Reduce the proportion of women of childbearing potential who have low red    
  blood cell folate concentrations 
 
Baseline: 24.5 percent of non-pregnant females aged 15 to 44 years did not have low red blood cell folate concentrations in 
2003–06  
Target: 22.1 percent  
Target-Setting 
Method: 
10 percent improvement 
Data Source: National Health and Nutrition Examination Survey (NHANES) CDC, NCHS 
 
Center Priority 2:  Prevent death and disability due to deep vein thrombosis (DVT) and pulmonary embolus 
(PE) relates to the following Healthy People 2020 goals: 
 
BDBS-12 Reduce the number of persons who develop venous thromboembolism (VTE) 
 
Baseline: 54.3 persons per 10,000 population aged 18 years and older developed venous thromboembolism (VTE) in 2007 (age 
adjusted to the year 2000 standard population)  
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Target: 48.9 per 10,000 population  
Target-Setting 
Method: 
10 percent improvement 
Data Source: National Ambulatory Medical Care Survey (NAMCS), CDC, NCHS; National Hospital Ambulatory Medical Care Survey 
(NHAMCS), CDC, NCHS 
BDBS-13 (Developmental) Reduce the number of adults who develop venous thromboembolism (VTE)  
  during hospitalization  
 
BDBS-13.1   (Developmental) VTE among adult medical inpatients.  
Potential Data 
Source: 
National Hospital Discharge Survey (NHDS), CDC, NCHS 




National Hospital Discharge Survey (NHDS), CDC, NCHS; Joint Commission on Accreditation of Health Care 
Organizations (JCAHO) survey 
 
Center Priority 3:  Reduce disparities in obesity and other health indicators in children, youth and adults 
with disabilities relates to: 
 
DH2.1  Increase the number of State and the District of Columbia health departments    
  that have at least one health promotion program aimed at improving the health    
  and well-being of people with disabilities. 
 
Baseline: 16 States and the District of Columbia had health promotion programs for people with disabilities in 2010  
Target: 18 States and the District of Columbia  
Target-Setting 
Method: 
10 percent improvement 
Data Source: Periodic Assessment of State Health Promotion Programs, CDC, NCBDDD 
 
 
DH-8       (Developmental) Reduce the proportion of people with disabilities who report    









NWS-9       Reduce the proportion of adults who are obese   
 
Baseline: 34.0 percent of persons aged 20 years and over were obese in 2005–08 (age adjusted to the year 2000 standard population)  
Target: 30.6 percent  
Target-Setting 
Method: 
10 percent improvement 
Data Source: National Health and Nutrition Examination Survey (NHANES), CDC, NCHS 
NWS-10.4   Children and adolescents aged 2 to 19 years   
 
Baseline: 16.2 percent of children and adolescents aged 2 to 19 years were considered obese in 2005–08  
Target: 14.6 percent  
Target-Setting 
Method: 
10 percent improvement 
Data Source: National Health and Nutrition Examination Survey (NHANES), CDC, NCHS 
PA-1  Reduce the proportion of adults who engage in no leisure-time physical activity. 
 
Baseline: 36.2 percent of adults engaged in no leisure-time physical activity in 2008  
Target: 32.6 percent  
Target-Setting 
Method: 
10 percent improvement 
Data Source: National Health Interview Survey (NHIS), CDC, NCHS 
 
Specific approaches to address these Center priorities are detailed in the strategic plan, and division-by-











Division of Birth Defects and Developmental Disabilities 
 
Our Vision, Approach and Priorities 
 
The Division of Birth Defects and Developmental Disabilities works to identify causes and prevention strategies 
for birth defects and developmental disabilities by applying a public health approach that incorporates three 
essential elements—surveillance or disease tracking, public health research to identify modifiable risk factors, 
and prevention research and programs.  The division’s unique expertise in surveillance and epidemiologic 
research on birth defects and developmental disabilities has yielded and continues to yield opportunities for 
prevention that promote healthy births and optimal development for all children.   Public health research is 
critical to identify risk factors for future prevention efforts which will allow us to decrease the prevalence of 
these very serious disorders. 
 
Building upon this history and approach, we have identified an ambitious, yet realistic set of goals, priorities 
and outcomes for the near term.  By leading in these efforts, we will move the entire field of birth defects 
surveillance, prevention and care forward in a substantial and tangible manner. 
 
Our Goals, Priorities and Outcomes for the Future 
 
Over the next four years, the goals of DBDDD are to: 
 
 Expand and enhance surveillance and tracking systems for birth defects and developmental disabilities, 
including follow up for longer term outcomes (e.g., survival, use of special education services, health 
care utilization).  
 Identify and understand the preventable risk factors (e.g., use of valproic acid during pregnancy) for 
birth defects and developmental disabilities. 
 Develop, evaluate and disseminate effective prevention strategies aimed at preventing the occurrence 
of birth defects and developmental disabilities. 
 Develop, evaluate and disseminate programs and strategies aimed at maximizing the quality of life for 
individuals with birth defects and developmental disabilities. 
 
To support achievement of these goals, DBDDD has identified the following priority objectives: 
 
 
Priority 1:  Enhance surveillance and research for autism and other developmental disabilities to monitor 
changes in prevalence and contributing risk factors, and better inform prevention policy and programs. 
 
Priority 2:  Prevent congenital heart defects and other major birth defects associated with obesity, 
diabetes, and medications. 
 
Priority 3:  Prevent alcohol-exposed pregnancy among reproductive age women to prevent fetal alcohol 
syndrome and other adverse effects of prenatal alcohol exposure. 
 
Priority 4:  Eliminate folic acid-preventable neural tube defects in the United States and globally. 
 
Priority 5:  Enhance the quality and usefulness of newborn screening data and programs.  
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By focusing on our goals and priorities, we intend to achieve the following outcomes: 
 
 Decrease or eliminate birth defects and developmental disabilities occurring due to known causes (e.g., 
isotretinoin exposure, insufficient folic acid). 
 Improve longer term outcomes of children with birth defects and autism and other developmental 
disabilities, and eliminate racial/ethnic disparities in these outcomes. 
 Identify preventable risk factors of birth defects and developmental disabilities and develop 
appropriate interventions to reduce these risks. 
 
How We Developed Our Priorities:  Building on Successes 
 
For over forty years, CDC has led the nation and world in birth defects surveillance.  This surveillance platform 
has enabled us to understand the magnitude of the problem, to pursue meaningful research into etiology and 
prevention, and to develop programs to address the underlying issues.  A few examples of the division’s past 
work in surveillance, public health research and prevention are briefly described. 
 
Characterizing the Problem through Surveillance 
 
Surveillance of birth defects and developmental disabilities has been carried out for years using several 
complementary surveillance systems.  Through these systems, DBDDD investigators and funded partners have 
pioneered techniques for population-based surveillance of birth defects and developmental disabilities.  These 
include the Metropolitan Atlanta Developmental Disabilities Surveillance Program (MADDSP), the Autism and 
Developmental Disabilities Monitoring Network (ADDM), the Metropolitan Atlanta Congenital Defects 
Program (MACDP), and fourteen funded state-based birth defects surveillance programs, surveillance of Fetal 
Alcohol Syndrome, and stillbirth surveillance pilots. 
 
Through this important, fundamental public health investment in surveillance, NCBDDD has established the 
critical infrastructure needed to determine that on an annual basis in the U.S. approximately 130,000 babies 
have a major birth defect, and over 500,000 children are diagnosed with a developmental disability.  And from 
surveillance data, we have determined that congenital heart defects (CHDs) represent the most common birth 
defects, affecting nearly 1% of infants in the U.S.  Population-based surveillance data has also allowed DBDDD 
investigators to assess survival of affected infants, and identify significant disparities in one-year survival by 
race/ethnicity for infants with certain birth defects such as congenital heart defects, Down Syndrome and 
spina bifida.    
 
In addition, over the past ten years, we have made great improvements in our understanding of autism 
spectrum disorder (ASD).  We have built a robust scientific infrastructure which has helped us to understand 
key features of ASD.  For example, the ADDM Network has established that 1 in 110 eight-year-old children 
has an ASD and that the condition occurs in all racial, ethnic, and socioeconomic groups, but is four times 
more likely to occur in boys than in girls.  We know that both advanced maternal and paternal age are risk 
factors for ASD, disparities exist in early identification and access to services for some children with ASD, and 
certain hazardous air pollutants such as methylene chloride, quinoline, and styrene warrant further 
investigation for a possible role in autism etiology.   
 
 




Population-based surveillance data identifies cases for NCBDDD’s public health research to identify 
preventable exposures associated with birth defects and developmental disabilities.    Epidemiological 
research has helped us to identify pre-pregnancy maternal obesity and diabetes as important risk factors for 
congenital heart defects, neural tube defects, and other major birth defects.  It has also helped identify the 
risk of birth defects associated with the use of specific medications during pregnancy such as SSRIs and certain 
antibiotics, thereby allowing for more informed risk versus benefit evaluation by women and their health care 
providers. 
 
Some relatively common exposures play an important role in the etiology of birth defects.  DBDDD’s 
population-based public health research has helped us to identify the following key risk factors for birth 
defects which are modifiable and therefore provide opportunities for interventions that can have a major 
public health impact: 
 
 1 in 8 women drink during pregnancy; 1 in 50 binge drink 
 Approximately 20% of women smoke in the month before pregnancy or in the first trimester of 
pregnancy 
 Approximately 10% of babies are born to women who have diagnosed diabetes before pregnancy or 
develop diabetes in pregnancy and 20 – 30% are born to women who are obese at the beginning of 
pregnancy 
 Approximately 50% of women use at least one prescription medication in pregnancy 
 
In the area of autism, our work in characterizing the magnitude of the condition has fueled the search for risk 
factors and causes of ASD and has informed key policy decisions to assist families in need of access to services 
and treatments.  However, we are at a critical juncture in our understanding of ASD.  We still do not know 
what is causing this condition with often debilitating symptoms.  We still do not know how much of the 
increase in prevalence is due to a true increase in risk and how much is due to extraneous factors.  Over the 
next ten years, we are likely to make unprecedented advances in our understanding, building upon the strong 
infrastructure we now have in place.  Recognizing that we are dealing with a serious developmental disability 
with unstable rates and no known cause, it is of critical importance that we amplify efforts and use all tools 
available to study this condition.  To do this, CDC is working in concert with other Federal and private agencies 
through the Federal Interagency Autism Coordinating Committee (IACC).  NCBDDD ASD activities provide an 
epidemiologic perspective to the 2010 IACC Strategic Plan addressing objectives such as: 
 
 7I- Supplement existing ADDM Network sites to use population-based surveillance data to conduct at 
least 5 hypothesis-driven analyses evaluating factors that may contribute to changes in ASD 
prevalence by 2012. 
 7L- Expand the number of ADDM sites in order to conduct ASD surveillance in younger and older age 
groups; conduct complementary direct screening to inform completeness of ongoing surveillance; and 
expand efforts to include autism subtypes by 2015. 
 3F- Initiate studies on at least 10 environmental factors identified in the recommendations from the 
2007 IOM report "Autism and the Environment: Challenges and Opportunities for Research" as 
potential causes of ASD by 2012. 
 




DBDDD’s efforts in prevention have focused on prevention of fetal alcohol syndrome and folic-acid 
preventable neural tube defects (NTDs).  Our studies reveal that there are 0.2 to 2.0 cases of FAS for every 
1,000 live births in certain areas of the U.S.  Fetal Alcohol Spectrum Disorders (FASDs), including FAS, refers to 
a range of effects that can result in prenatal alcohol exposure. Researchers estimate that there are at least 
three times as many cases of FASDs as FAS alone. FASDs are 100% preventable and may cause lifelong 
physical, behavioral, and cognitive disorders, ranging from mild to severe.  The lifetime cost for one individual 
with FAS in 2002 was estimated to be $2 million.  NTDs remain a significant cause of infant mortality and 
childhood morbidity globally.  There are 3,000 NTD-affected pregnancies in the U.S. each year, and lifetime 
medical costs for a child with spina bifida are estimated to be $560,000.  Globally more than 300,000 infants 
are born with NTDs each year.  Some successes from these two programs include: 
 
Project CHOICES – An evidence-based screening and brief intervention program that counsels and educates 
women of reproductive age about the impact of drinking during pregnancy.  We are currently evaluating the 
effectiveness of bundling a tobacco cessation intervention with Project CHOICES, and are working with 
SAMHSA, HRSA, IHS and the CDC STD program to implement the Project CHOICES screening and brief 
intervention model in the context of these various delivery systems. 
 
Folic Acid Fortification – Surveillance and research conducted by NCBDDD and others throughout the world 
demonstrated the important role of periconceptional folic acid in preventing NTDs.  These findings resulted in 
a major population-level policy intervention:  mandatory folic acid fortification of enriched cereal grain 
products in the United States.  This intervention resulted in the prevention of an estimated 1,000 NTDs per 
year since its full implementation in 1998.  NCBDDD has also developed a global plan for elimination of folic 
acid-preventable NTDs, and is working closely with external partners and the FDA on a food additive petition 
to allow folic acid fortification of corn masa flour. 
 
Currently global micronutrient fortification programs that include folic acid are preventing only about 9% of 
total annual cases of folic-acid preventable NTDs.  Expanding the number of developed and developing 
countries with mandatory folic acid fortification of high consumption staples can potentially safely eliminate 
the majority of NTDs.  Current research and increasing   fortification efforts have demonstrated the ability to 
eliminate those NTDs that are sensitive to folic acid.  Assuming 50%-70% of NTDs are folic acid-preventable, 
and assuming an annual prevalence of 300,000 NTDs, worldwide folic acid fortification could lead to the 
prevention of 150,000-210,000 NTDs per year.  
 
In the area of autism and developmental disabilities prevention the Division has focused on the opportunity to 
improve the outcomes of children with autism through an extensive health communication campaign to 
identify children with developmental delays as early as possible.  The “Learn the Signs. Act Early.” (LTSAE) an 
education program for providers, parents and early educators, aims to improve awareness of early, healthy 
child development milestones.  The intent of this program is to help parents, caregivers and others interacting 
with a child to quickly identify physical or developmental delays, especially focused on cognitive, emotional 
and social delays, link the child and family to early intervention services, thereby achieving the best possible 
outcomes.    
 
After three years of program implementation, analyses of data show that pediatricians who were aware of 
LTSAE indicated that they were significantly more confident discussing cognitive development with parents, 
that they were more likely to be aware of resources available for referral and treatment, and that they were 
likely to have resources to educate parents.  Preliminary results of a HealthStyles survey show that parental 
awareness of the campaign correlated with greater knowledge about childrens’ developmental milestones, 
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increased confidence in talking with teachers and doctors about child development issues, and an increased 
ability to find appropriate services for children with delays.   
 
To maximize the potential public health impact of future work, DBDDD has prioritized work on diabetes, 
obesity, and medications used during pregnancy.  These risk factors were selected based on their prevalence 
and the epidemiological evidence showing the strength of their association with major birth defects.  (See 
Appendix IV for a brief overview of major birth defects.)  Successful efforts to modify these preventable 
exposures should prevent major birth defects and the lifelong consequences that accompany these serious 
disorders.   
 
Yet another fundamental component of the Center’s work involves newborn screening.  An effective screening 
program is an important precursor to intervention and treatment programs.   Newborn screening identifies 
conditions that can affect a child's long-term health or survival.  Early detection, diagnosis, and intervention 
can prevent death or disability and enable children to reach their full potential.  Each year, millions of babies in 
the U.S. are routinely screened, using a few drops of blood from the newborn's heel, for certain genetic, 
endocrine, and metabolic disorders.  DBDDD works closely with other agencies and CDC programs to 
implement, evaluate, and enhance screening programs to optimize outcomes for affected children identified 
through newborn screening. 
 
  
DBDDD’s Strategic Plan 
 
 
Characterize the Problem:  Prevalence, Incidence and Distribution 
 
Four Year Outcome:   Data on the prevalence of Autism Spectrum Disorders (ASDs) among 8-year-old children 
will be reported biennially by the ADDM Network to monitor the changing prevalence of these serious 
conditions. These data will be used for national/state/local policy and planning to better meet the needs of 
children with ASDs and their families. 
 
Progress Indicators: 
1. Publish updated ASD prevalence estimates among 8-year-old children every two years, within 6 
months of final submission of data to CDC, and assess factors potentially contributing to the rising 
prevalence. 
2. Complete the first “Early ADDM” study to estimate the prevalence of ASDs among 4-year-old children; 
initiate prevalence study to follow up this initial cohort at age 8.   (IACC Objective 7L) 
3. Evaluate the presence of racial and ethnic disparities in the proportion of children with ASDs having a 
first evaluation by 36 months of age. 
4. Implement a data dissemination and communication plan to increase the utility of ADDM data and 
improve policy and practice. 
Priority 1:  Enhance surveillance and research for autism and other developmental disabilities to monitor 
changes in prevalence and contributing factors, and better inform policy and program activities. 
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Four Year Outcome:   We will have a better understanding of how changes in diagnosis and other system 
issues influence trends in ASD prevalence and ensure that knowledge is disseminated to policy makers and 
program leaders at the national, state, and local levels. 
 
Progress Indicators: 
1. Evaluate the impact of changes in awareness and diagnostic practices on ASD prevalence trends 
through data and modeling approaches.   (IACC Objective 7I) 
2. Complete analyses to identify factors that may explain:  a) why certain groups of children are more 
likely to be identified by community providers as having ASD; b) how often our surveillance case 
definition matches the providers’ impressions; c) whether these factors are changing over time; d) the 
impact of these factors on ASD prevalence trends; and e) what recommendations should be made to 
address the factors identified (e.g., increased ASD screening for children in certain groups, promoting 
the use of robust diagnostic instruments.)  (IACC Objective 7I) 
 
Conduct Research into Risk and Protective Factors 
 
Four Year Outcome:   Based on data from the Study to Explore Early Development (SEED) Phase I, a 
population-based study of epidemiologic risk factors for ASD, we will have a better understanding of the 
strength of the association of ASD with exogenous hormones, such as infertility treatments, and maternal 
infections with ASD that will inform potential action for prevention or intervention. 
 
Progress indicators:   
1. Complete enrollment and data collection for 6 SEED, Phase I sites.  
2. Initiate a second round of SEED data collection (SEED Phase II) to increase the total SEED pooled 
sample size for investigation of SEED’s high priority risk factors, thereby enhancing the potential for 
identifying important ASD risk factors that will inform action for prevention or intervention.  (IACC 
Objective 3F) 
3. With SEED Phase I data, investigate the role of exogenous hormones, such as infertility treatments, and 
maternal infections as high priority risk factors for ASD.  (IACC Objective 3F) 
Develop, Implement and Translate Feasible and Effective Interventions 
 
Four Year Outcome:   Learn the Signs.  Act Early.  campaign materials are relevant, effective and are used by 
public, professional and private organizations that serve parents and caregivers of young children. 
 
Progress Indicators: 
1. Reassess the appropriateness and adequacy of the current LTSAE materials to meet the current 
information needs of parents of young children and other caregivers.  
2. Refine campaign materials and implementation strategies to improve their reach and effectiveness in 
meeting the needs of the public, professional and private organizations who serve parents and 
caregivers of young children.  
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3. Work with the Health Resources and Services Administration (HRSA) to explore campaign 
implementation strategies and the effectiveness of the campaign in reaching and educating specific 
population subgroups.  
4. Broadly disseminate LTSAE materials through organizations, various systems and professional and lay 
efforts serving young children and their families (e.g., Nurse Family Partnerships, WIC, etc.)  
Four Year Outcome:   Effective strategies exist and are used in professional practice to reduce racial/ethnic 
disparities in the identification of ASD and other developmental disabilities. 
 
Progress Indicators: 
1. Explore strategies to reduce racial/ethnic disparities in the identification of ASD and other 
developmental disabilities by enhancing the Learn the Signs. Act Early. health communications 
campaign efforts among special populations such as low-income groups. 
2. Continue collaborative work with HRSA to carry out two projects addressing early identification among 
lower socioeconomic status groups and Hispanic populations.  
3. Identify and evaluate strategies to reduce racial/ethnic disparities in the identification of ASD and 
other developmental disabilities.  
4. Develop partnerships to disseminate proven strategies for improving provider and parental knowledge 







Characterize the Problem:  Prevalence and Distribution 
 
Four Year Outcome: Improved birth prevalence and survival estimates for individual birth defects by specific 
subpopulations are used for national/state/local policy and planning to better meet the needs of families 
affected by major birth defects. 
 
Progress indicators: 
1. Develop standards for data acquisition and clinical review in birth defects surveillance to improve 
program assessment and evaluation and guide ongoing program development. 
2. Develop strategies to maximize the potential of electronic medical records to improve the accuracy 
and efficiency of birth defects surveillance. 
3. Pool surveillance data from multiple state-based surveillance programs to evaluate the survival of 
infants with specific birth defects in the United States and to identify social determinants of health 
measured at the community level that influence survival. 
4. Make data more readily available to programs and policy makers by launching an interactive, web-
based version of the annual birth defects surveillance data reported to the National Birth Defects 
Prevention Network. 
 
Priority 2:  Prevent congenital heart defects and other major birth defects associated 
with obesity, diabetes and medications.   
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Four Year Outcome:  Understanding the contribution of birth defects to longer term outcomes (i.e., beyond 
infancy) and the economic impact of specific birth defects will inform medical and public health practices, 
provide key updated information on prognosis to parents and health care providers, and improve health and 
support services.  Linking data from birth defects surveillance programs to data sets of other health outcomes 
and administrative data will allow investigators to more fully characterize the public health impact of birth 
defects and allow for the examination of research questions of greater policy and clinical relevance.   
 
Progress indicators: 
1. Link data from birth defects surveillance systems with pediatric cancer registries, special education 
data, educational achievement data, and other available outcome data to identify opportunities to 
improve the longer term outcomes of children with birth defects. 
2. Link data from birth defects surveillance systems with health care cost data (e.g., Medicaid claims) to 
examine the economic burden associated with birth defects. 
 
Conduct Research into Modifiable Risk and Protective Factors for Major Birth Defects 
 
Four Year Outcome:  Safety and risk information on medications frequently used by reproductive-aged women 
and used during pregnancy is disseminated and used to assist women and their health care providers in 
making informed treatment decisions.   
 
Progress indicators: 
1. Identify medications that are most frequently used immediately before and during pregnancy to assess 
their safety or risk to the fetus and allow an appropriate evaluation of risk versus benefit.  In 
collaboration with AHRQ, FDA, and NIH, develop a framework for an ongoing, systematic, evidence-
based review to evaluate the safety or risk of specific medications during pregnancy.  
2. Assess the percentage of all medications (prescription and over-the-counter) with sufficient data to 
determine the safety or risk when used during pregnancy. 
3. Follow up on key findings from the National Birth Defects Prevention Study showing associations 
between specific medications (e.g., specific SSRIs, antibiotics) and major birth defects.  Additional data 
will inform guidance to clinicians on the safest choices for managing maternal illness during pregnancy 
and will prevent the occurrence of major birth defects.  
Four Year Outcome:  Collaborate with NCCDPHP to evaluate potential effect modifiers for diabetes and 




1. Evaluate diet quality and other nutritional factors as potential effect modifiers of the association 
between diabetes/obesity and major birth defects.   
2. Assess physical activity and type of obesity as potential independent risk factors and as potential effect 
modifiers of the risk of major birth defects.  
3. Identify and evaluate potential policy changes that could be implemented related to diabetes 





Develop, Implement and Translate Feasible and Effective Interventions 
 
Four Year Outcome:  Programs to reduce birth defects and other adverse pregnancy outcomes are evaluated, 
disseminated, and implemented. 
 
Progress Indicators: 
1. In coordination with the Division of Diabetes Translation (DDT), the Division of Nutrition, Physical 
Activity, and Obesity (DNPAO), and the Division of Reproductive Health (DRH), and with input from 
other experts and stakeholders, develop a public health framework for diabetes and pregnancy that 
will:  a) identify and prioritize data collection; and b) recommend prevention and health promotion 
strategies to reduce adverse pregnancy outcomes associated with pregestational diabetes.  
2. Develop and implement effective policy approaches and other interventions to improve reproductive 





Develop, Implement and Translate Feasible and Effective Interventions 
 
Four Year Outcome:  The percentage of primary health care providers who always screen for alcohol use and 
conduct brief interventions with women of reproductive age who screen positive for risky drinking will 
increase by 10%. 
 
Progress Indicators: 
1. Promote alcohol screening and brief intervention in primary care settings serving women of 
reproductive age. 
2. Determine the potential impact of “bundling” a number of prevention strategies, e.g.,  – brief alcohol 
counseling with smoking cessation strategies. 
3. Develop, disseminate and implement recommendations based on research conducted regarding the 
effectiveness of alcohol screening and brief intervention in specific settings and when bundled with 
other prevention programs. 
4. Work with alcohol programs in NCIPC and NCCDPHP to identify primary care collaborators to support, 
monitor and evaluate implementation of alcohol screening and intervention guidelines for women of 
reproductive age.   
Four Year Outcome:   Increased awareness of the dangers of alcohol use during pregnancy among women and 




1. Assess knowledge of alcohol risk during pregnancy among women of reproductive age.  
2. Initiate activities to assess knowledge of alcohol risk during pregnancy among health care providers. 
Priority 3:  Prevent alcohol-exposed pregnancy among reproductive age women to 
prevent fetal alcohol syndrome and other adverse effects of prenatal exposure. 
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3. Clarify messaging around alcohol use and pregnancy for women of reproductive age and their health 
care providers. 
4. Target awareness and educational activities to women of reproductive age and their healthcare 
providers.  
Four Year Outcome:   Increase use of Project CHOICES among a wide range of service providers serving women 
at risk of an alcohol exposed pregnancy. 
 
Progress Indicators: 
1. Implement activities to assess the feasibility and impact of Project CHOICES in settings serving women 
at risk of alcohol-exposed pregnancy.  
2. Establish the training and technical assistance infrastructure to support Project CHOICES. 
3. Modify and evaluate Project CHOICES based on feasibility studies to meet the needs of service 
providers of women at risk of an alcohol-exposed pregnancy.  
4. Disseminate Project CHOICES and provide technical assistance to a wide range of service providers 
serving women at risk of an alcohol-exposed pregnancy. 
 
Four Year Outcome:   National data on populations at risk for an alcohol-exposed pregnancy are available and 
disseminated to states and national organizations serving women of reproductive age to inform FASD 




1. Work with National Center for Health Statistics (NCHS)/National Survey of Family Growth (NSFG) to 
better define the at-risk population for alcohol-exposed pregnancy. 






Characterize the Problem:  Prevalence, Incidence and Distribution 
 




1. Work with the World Health Organization and others to determine optimal blood folate concentrations 
for NTD prevention, by examining available scientific data and convening an expert panel.   
2. Disseminate recommendation on optimal blood folate concentrations and develop guidance on 
appropriate folic acid fortification strategies for low- to middle-income countries.  (Note:  high income 
countries have effective fortification strategies in place.  Many of these strategies focus on grain 
fortification, but in most cases this excludes corn masa fortification.) 







Four Year Outcome:   Prevalence of NTDs among Hispanic women is not more than 10% higher than the 
prevalence in non-Hispanic whites. 
 
Progress Indicators: 
1. Work with FDA, GRUMA (a major manufacturer of corn masa flour products), American Academy of 
Pediatrics, Spina Bifida Association, March of Dimes and other partners to develop a food additive 
petition to allow folic acid fortification of corn masa flour.   
2. Conduct formative research to gauge the level of consumer acceptance of fortified corn masa flour and 
related products. 
3. Contribute safety data to be used in the development of a food additive petition to allow fortification 
of corn masa flour.   
 
Global 
Four Year Outcome:   Number of countries fortifying highly consumed staples with folic acid increases by 20% 
(from 53 to 64). 
 
Progress Indicators: 
1. NCBDDD supports the work of the International Micronutrient Malnutrition Prevention and Control 
Program (IMMPCt) and others in the prevention of NTDs globally (e.g., supporting existing program 
efforts, initiating new program efforts, providing scientific and technical support for monitoring and 
surveillance).  
2. CDC provides technical assistance to inform policy recommendations and NTD surveillance activities in 
countries engaged in folic acid fortification efforts. 
3. Broad consensus on optimal blood folate level for NTD prevention is established and used to develop 
guidance and monitor the impact of fortification efforts globally.  
4. CDC supports development of birth defects surveillance for NTDs in at least two low- to middle-income 




Four Year Outcome: New functional screening programs are implemented as recommended by the Health 
and Human Services Secretary, and existing screening programs are enhanced and evaluated, to assess 
and optimize outcomes for affected children identified by newborn screening. 
 
Progress Indicators: 
1. Co-sponsor a critical cyanotic congenital heart disease (CCCHD) workgroup meeting and assist with 
dissemination of the outcomes of that meeting to develop protocols for CCCHD screening. 
2. Develop and implement a strategy to evaluate CCCHD screening programs.   
3. Publish methodologies and outcome data on long-term follow-up of children with inborn errors of 
metabolism. 
Priority 5:  Enhance the quality and usefulness of newborn screening data and programs.   
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4. Develop a newborn screening follow-up quality improvement educational module for primary care 
providers. 
5. Finalize a national contingency plan for newborn screening, assist state programs with developing 
standard operating procedures to carry out the plan in the event of emergencies, and maintain and 




Division of Blood Disorders 
 
Our Vision, Approach and Priorities 
 
Millions of Americans have inherited or acquired conditions of the blood that result in adverse health 
outcomes.  Initially focused on coagulation disorders and conducting research to determine the hematological 
mechanisms for clotting, the Division’s activities have expanded over the years to strengthen our hemophilia 
and blood safety programs and establish new programs focused on preventing and reducing complications 
and death caused by nonmalignant bleeding, clotting and other blood disorders such as Sickle Cell Disease, 
thalassemia, and Diamond Blackfan Anemia. 
 
Data collection and analysis has always been a central feature of DBD’s work, though from a public health 
standpoint, these activities have been carried out from a laboratory or clinical perspective.  In recent years 
DBD’s focus has shifted to a population-based public health model that addresses the critical public health 
challenges associated with bleeding, clotting and other blood disorders and related secondary conditions.  This 
comprehensive public health approach includes, in addition to data collection and monitoring, research to 
identify preventable or modifiable risk factors, developing and testing prevention strategies and assuring 
widespread adoption of effective prevention strategies.   
 
Working with our many public health partners – other federal and state agencies, academia, and professional 
and community-based organizations – DBD strives to improve the lives of people at risk or affected by blood 
disorders. 
Our Goals, Priorities and Outcomes for the Future 
 
The goals of DBD are to: 
 Establish blood disorders as a public health priority 
 Understand the causes of and risk factors for blood disorders 
 Understand and minimize occurrence and complications of blood disorders  
 Develop and evaluate evidence-based interventions for blood disorders 
 Ensure that people with or at risk for blood disorders have access to credible health information 
 
The Division has prioritized its work with an immediate focus on nonmalignant blood disorders with the 












Priority 1:  Prevent clotting disorders – deep vein thrombosis and pulmonary embolism. 
 
Priority 2:  Prevent and control complications resulting from hemoglobinopathies, with a focus 
on Sickl  Cell Disease and thalassemia. 
 
Priority 3:  Prevent and control complications resulting from bleeding disorders such as 





In meeting our goals and priorities, we intend to contribute to achieving the following outcomes: 
 
 Reduce the incidence of deep vein thrombosis/pulmonary embolism, and prevent related mortality 
and serious morbidity. 
 Improve the life expectancy of people with Sickle Cell Disease. 
 Reduce the morbidity and mortality related to bleeding disorders in women, particularly during 
pregnancy. 
 Prevent emerging morbidities of people with bleeding disorders. 
 
How We Developed Our Priorities 
 
Non-malignant blood disorders such as deep vein thrombosis/pulmonary embolism (DVT/PE), Sickle Cell 
Disease (SCD), thalassemia, hemophilia and von Willebrand disease (VWD) affect millions of people in the 
United States.  They cut across the boundaries of age, race, sex and socioeconomic status and result in 
significant healthcare costs, complications, co-morbidities and sometimes death. 
 
Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE) 
 
DVT/PE are under-diagnosed, serious, potentially preventable medical conditions associated with an 
estimated 100,000 deaths each year.  The precise number of people affected by DVT/PE is unknown, however 
estimates range from 350,000-600,000 annually with associated healthcare costs up to $10 billion.  Sudden 
death is the first symptom in about a quarter of the people who have a PE.  DVT/PE also poses important 
problems for women; there is a five times greater risk for developing DVT/PE during pregnancy, the post 
partum period, and while taking hormonal contraceptives.  Other major risk factors include advance age, 
immobility, surgery, and obesity.  While several genetic risk factors have also been identified, an estimated 
one-third to one-half of DVT/PE cases have unknown risk factors.     
 
Because DVT/PE occurs in diverse healthcare settings as well as in the community, it is diagnosed and 
managed by myriad providers.  While evidence-based guidelines on DVT/PE prophylaxis and management for 
hospitalized patients exist, about two-thirds of cases occur after patient discharge.  Therefore, a need exists to 
develop evidence-based standards for outpatient DVT/PE prophylaxis and management.  In addition, there is a 
need to increase the public’s awareness of the risk factors and symptoms of DVT/PE, and provider knowledge 
of, and adherence to, guidelines for the management and treatment of these conditions.   
 
Hemoglobinopathies – Sickle Cell Disease (SCD) and thalassemia 
 
Although hemoglobinopathies can affect people of all ethnicities, they are most common among ethnic 
minorities and represent a major health disparity.  SCD primarily affects people of African descent and is 
becoming increasingly prevalent among Hispanics.  Thalassemia is most common among people whose 
ancestors come from the Mediterranean region, the Middle East, India, Southeast Asia, Southern China and 
Africa. In the U.S, there are approximately 100,000 people with SCD and an estimated 3 million with Sickle Cell 
trait.  Up to $1.1B in total annual healthcare costs are associated with SCD.   Thalassemia is thought to affect 
approximately 1,000 persons, but the number of carriers of the trait is unknown as is the amount of 
healthcare expenditure.  While many advances have been made, persons with SCD have a three decades 
shorter life expectancy than other Americans and can experience repeated episodes of severe pain, organ 
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damage, serious infections or anemia.  People with the severe anemia form of thalassemia – Cooley’s Anemia- 
usually do not live into adulthood without treatment often requiring monthly blood transfusions and 
medication to remove iron overall.   
 
There is a lack of understanding of the overall population impact of hemoglobinopathies.  Data is needed to 
identify risk factors, barriers to care, and effective inventions and prevention measures for those affected by 
these disorders.  In addition, public and healthcare provider awareness and education is needed on how to 
treat and manage these rare disorders. 
 
Bleeding Disorders  
 
There are an estimated 20,000 people (mostly males) with hemophilia in the United States with healthcare 
costs approaching $3 billion a year.  People with hemophilia (PWH) have spontaneous internal bleeding and 
prolonged bleeding after an injury or surgery that can lead to long-term damage and chronic conditions such 
as a disabling joint disease.  Approximately 15-20% of hemophilia patients develop an inhibitor where the 
individuals’ immune system destroys the clotting factor replacement products, making the treatments 
ineffective, increasing hospitalization rates and co-morbidities.  A single patient with complications and an 
inhibitor can have over $1M in treatment costs annually.  Research on how and why a PWH may develop an 
inhibitor is needed to identify effective prevention/intervention strategies. 
 
VWD is a bleeding disorder that affects 1% of all women in the U.S. (approximately 1 in 100) and is associated 
with an increased risk for miscarriage, bleeding during pregnancy, and postpartum hemorrhage.  Women with 
VWD have a maternal mortality rate 10 times higher than that of women without VWD.  Many women learn 
to live with the problems their bleeding causes, such as heavy menstrual periods, and do not realize that they 
may have a blood disorder.  VWD is often not diagnosed and can result in costly and inappropriate treatment 
such as unnecessary hysterectomies.  With early identification, women with bleeding disorders can avoid 
many of the associated complications and improve their quality of life.  Increasing the awareness of women 
about the symptoms of a bleeding disorder, and education and guidelines for healthcare providers in early 
recognition and appropriate referral for treatment is needed. 
 




Characterize the problem:   Prevalence, Incidence and Distribution 
 




1. Work with CDC colleagues (DHQP, DHDSP, NCHS) and external partners (such as AHRQ, ASH, CMS, 
NHLBI) to assess the strengths and limitations of the use of existing datasets as sources of information 
for DVT/PE surveillance.  
2. Support investigator-initiated population-based surveillance pilot projects to allow for the evaluation 
of the effectiveness of multiple approaches for DVT/PE surveillance, and improve our understanding of 
opportunities for, and impact of, prevention efforts over the long term.  
Priority 1:  Prevent clotting disorders – deep vein thrombosis and pulmonary embolism. 
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3. Develop and implement a viable surveillance system for DVT/PE based on our evaluation of existing 
datasets and the surveillance pilot projects. 
Develop, Implement and Translate Feasible and Effective Interventions 
 
Four Year Outcome:   An increase in knowledge and awareness of the general public and healthcare providers 
about the prevention of DVT/PE. 
 
Progress Indicators: 
1. Assess the awareness of risk factors, signs, symptoms, and prevention of DVT/PE, among the general 
public and healthcare providers and identify knowledge gaps.  
2. Collaborate with professional and community-based organizations to develop and implement a public 
awareness campaign to educate the public and health care providers on the risk factors, signs, and 
symptoms associated with DVT/PE. 
3. Collaborate with professional organizations to develop health care provider education and training 
programs that promote evidence-based practice for the prevention, diagnosis and treatment of 
DVT/PE.   
Four Year Outcome:   An increase in the use of evidence-based prevention and management guidelines for 
DVT/PE in the hospital and outpatient settings. 
 
Progress Indicators: 
1. Work with appropriate professional organizations (such as AAP, ACOG, AMA, ASH and the Joint 
Commission) and federal partners to assess existing private sector, national and international 
guidelines for the prevention and management of DVT/PE. 
2. Assess healthcare provider knowledge and use of DVT/PE guidelines. 
3. Develop and disseminate a uniform set of evidence-based prevention and management guidelines for 
DVT/PE in the hospital and outpatient settings, to promote interventions for high-risk inpatients and 
risk reduction for the general population. 
4. Collaborate with appropriate professional organizations (such as AAP, ACOG, AMA, ASH and the Joint 
Commission) and federal partners to implement guidelines. 





Characterize the Problem:  Prevalence, Incidence and Distribution 
 
Characterize the problem:   Prevalence, Incidence and Distribution 
 
Four Year Outcome:    Hemoglobinopathies surveillance system (developed as part of the Registry and 
Surveillance of Hemoglobinopathies–RuSH-project) tracks key health indicators for people with 
hemoglobinopathies in order to  provide the research, public health, clinical and consumer communities data 
to inform research, services, and policy agenda.  
Priority 2:  Prevent and control complications resulting from hemoglobinopathies, with a 






1. Establish pilot surveillance projects for SCD and thalassemia in six states (RuSH). 
2. Fund 1-2 additional states to cover 50% of African Americans and 50% of the Asian Population in the 
U.S. 
3. Develop case definition, common data sets, and indicators for longitudinal monitoring. 
4. Conduct validation studies to evaluate the utility of administrative and other existing data sources for 
hemoglobinopathy surveillance and epidemiologic research. 
5. Publish surveillance reports and conduct analysis projects using year-one data. 
6. Generate baseline indicators to measure 4-6 Healthy People 2020 objectives that have been 
determined measurable using RuSH surveillance. 
7. Characterize the population of people with SCD and thalassemia, (e.g., accurate prevalence estimates, 
healthcare utilization, treatment adherence, co-morbidities). 
 
Conduct Research into Risk and Protective Factors 
 
Four Year Outcome: Identification of factors (genetic, environmental, behavioral, and health services) that 
lead to improved health outcomes of people with SCD and thalassemia to inform public health, clinical and 
consumer communities and policymakers.   
 
Progress Indicators: 
1. Evaluate models of health services delivery for people with SCD and thalassemia to assess impact on 
health outcomes. 
2. Identify and evaluate the impact of genetic, environmental, behavioral and other risk factors such as 
micronutrient deficiencies, co-morbidities and co-occurring conditions, and access to health services 
on health outcomes of persons with SCD and thalassemia.  
3. Examine the economic burden of SCD and thalassemia to identify areas where there are opportunities 
to reduce economic burden while simultaneously improving health outcomes of persons with SCD and 
thalassemia. 
 
Develop, Implement and Translate Feasible and Effective Interventions 
 
Four Year Outcome:  An increase in knowledge and awareness of the public and healthcare providers about 
treatment for, and management of, people with SCD and thalassemia. 
 
Progress Indicators: 
1. Collaborate with professional and community-based organizations to develop and implement a public 
awareness campaign to educate the public and healthcare providers on SCD and thalassemia. 
2. Collaborate with professional organizations to develop health care provider education and training 
programs on the treatment and management of people with SCD and thalassemia.  
3. Provide community-based organizations and state and local health departments’ support, 
coordination, and technical assistance in conducting SCD education and training activities for parents, 






   
 
 
Characterize the Problem:  Prevalence, Incidence and Distribution 
 




1. Evaluate the current HTC-based bleeding disorders surveillance system (Universal Data Collection 
program - UDC) in terms of current representativeness and use.  
2. Engage relevant healthcare provider groups and policy makers to make recommendations for potential 
expanded uses and required data element modifications. 
3. Provide recommendations for deleting/adding information to be collected, as the basis for improved 
research and prevention efforts. 
4. Modify UDC data elements as appropriate for research and prevention efforts. 
Conduct Research into Risk and Protective Factors 
 
Four Year Outcome: Improved capacity for epidemiologic research studies of populations with inherited 
bleeding disorders such as hemophilia and VWD. 
 
Progress Indicators: 
1. Evaluate the quality and utility of existing datasets to describe the epidemiology of blood disorders 
(e.g. burden of disease, risk factors, co-morbidities, mortality, and disability).  
2. Summarize and publish existing datasets as resources to study the epidemiology of blood disorders.  
3. Address information gaps by collecting information not previously available 
4. Disseminate and implement recommendations to enhance existing datasets. 
5. Conduct research to be used as the basis for developing intervention strategies. 
Develop, Implement and Translate Feasible and Effective Interventions 
 
Four Year Outcome:  Increased use of intervention strategies by hemophilia treatment providers, to reduce 




1. Evaluate the cost effectiveness of genotyping hemophilia patients to identify those at high risk for 
inhibitor development and, as appropriate, the need for alternative treatment strategies. 
2. Establish a baseline rate of patients receiving routine inhibitor screening. 
3. Assess inhibitor screening practices of hemophilia treatment providers. 
4. Develop and disseminate national guidelines for inhibitor screening. 
Priority 3:   Prevent and control complications resulting from bleeding disorders such as 




Four Year Outcome:  An increase in the knowledge and awareness of women about the symptoms 
(menorrhagia, nosebleeds, postpartum hemorrhage) of a bleeding disorder such as VWD. 
 
Progress Indicators: 
1. Conduct a survey to assess women’s (ages 18-25) overall awareness and knowledge of bleeding 
disorders and communication channels they would use to learn more about bleeding disorders.  
2. Collaborate with professional organizations and community-based organizations to develop and 
implement an education campaign for women about the signs and symptoms of bleeding disorders. 
Four Year Outcome:   Increased proportion of OB/GYNs engaged in early identification and appropriate 
referral of women with bleeding disorders. 
Progress Indicators: 
1. Conduct a survey of OB/GYNs’ awareness, knowledge and practices relating to the identification of 
women’s bleeding disorders.   
2. Develop and disseminate recommendations to OB/GYNs. 
3. Collaborate with professional organizations, such as ACOG and ASH to implement identification and 
referral guidelines. 
Four Year Outcome:  Increased use of effective transition plans by young people with blood disorders to 
obtain the care needed to maintain health and prevent secondary complications in adulthood. 
 
Progress Indicators: 
1. Identify and evaluate existing materials and communication modalities for transition planning as it 
pertains to young people with blood disorders. 
2. Collaborate with professional and consumer organizations to address information gaps and develop 
curriculum on self-management skills needed by young people with blood disorders for successful 
transition into adulthood. 
Collaborate with professional and consumer organizations to disseminate, promote and evaluate the adoption 





Division of Human Development and Disability 
 
Our Vision, Approach and Priorities 
 
The Division of Human Development and Disability was created to prevent secondary conditions and enhance 
the quality of life among persons who already have a disability.  DHDD combines multiple funding lines to 
promote healthy development and reduce health disparities across the life course for persons with or at risk 
of disability.   Our approach is evolving through three Institute of Medicine (IOM) reports (1991, 1997, 2007), 
two Surgeons General reports, development of 20 HP2020 objectives, and the Affordable Care Act (ACA) to 
include disability populations within general public health activities.  The DHDD programs have contributed to 
the maturation that the field of disability and public health has experienced through surveillance, 
epidemiological research, and implementation of effective policies, programs and practices.   
 
DHDD’s diverse programs and range of activities are unified by its life course mission.  Healthy development 
across the life course is a major focus of the division.  Beginning prior to birth, a program of early parenting 
intervention has been demonstrated to optimize child development and prevent mild developmental delays 
and disorders to children born into poverty.  Its roll-out for large-scale implementation through the Early Head 
Start network is underway.  Working with HRSA, the Early Hearing Detection and Intervention (EHDI) program 
monitors identification and intervention for newborns with hearing loss.  During childhood, the health and 
developmental needs of children with complex disabling conditions, such as spina bifida and muscular 
dystrophy, and their families are characterized to determine public health interventions needed to promote 
optimal outcomes.  DHDD collaborates to articulate and implement a public health approach to addressing 
successful transition of youth with disabilities into adulthood.  Finally, DHDD has developed a network of state 
Disability and Health programs that monitor and intervene to meet the public health needs of adolescents, 
adults and elders with disabilities. 
 
Our Goals, Priorities and Outcomes for the Future 
 
Building upon our history and public health knowledge, DHDD has identified the following goals for the future:  
 
 Improved health and developmental outcomes for children. 
 Improved quality of life and life expectancy of people with disabilities. 
 Eliminated health disparities of children, youth and adults with disabilities. 
Identified Public Health Needs for our Populations 
 
 Newborns are at risk of developmental delays if hearing loss is not detected and interventions 
received.  Effective newborn hearing screening can be assured by understanding the prevalence of 
hearing loss, audiological exams and referrals for intervention after screening newborns, incidence of 
screening, referrals and interventions, and distribution of each regionally and by state.  
 
 Children living in poverty are at higher risk for developmental delays than children not living in poverty.  
One way to address this is to consider parenting interventions as public health practices to mitigate the 




 Disparities are evident across multiple health indicators for persons with disabilities.  For example, 
obesity rates in children/youth with disabilities exceed those without disabilities (22.5% versus 15.74%) 
and this disparity is even greater in adults (37.6% versus 23.7%).  Persons with mobility and intellectual 
limitations are at highest risk of obesity.  Reducing disparities in obesity rates requires expanding 
research to increase our understanding on how to best develop, implement and then translate 
knowledge gained into feasible and effective public health interventions.   By focusing on obesity and 
other health indicators, we are aligning our work with a framework developed by IOM in 2008, and 
creating the potential to work on broader, related issues such as barriers to health promotion and 
social participation. 
 
 Unmet health care needs of persons with disabilities are more than double that of the general 
population.  Even with insurance, 16% of persons with disabilities report skipping needed health care in 
the previous year because of cost compared with 5.8% of the rest of the population.  Adults with 
disabilities are more likely to rely on public insurance such as Medicaid or Medicare, and health care 
providers may be less likely to accept these forms of insurance.  For those without insurance, these 
numbers reach 61% for persons with disabilities and 31% for others.  Identifying prevalence of selected 
health care services, the incidence in which they occur, and how these services vary in their distribution 
between regions and states is required to address the problem.  Model programs of conducting 
accessibility assessments and providing training to providers highlight potential public health 
interventions.  
 
 Disability status is frequently overlooked as a demographic characteristic in surveying the health of 
populations.  Of approximately 44 currently inventoried CDC surveillance systems, only 3 include 
disability status identifiers.  Disability indicators are required by ACA for use in public health surveys to 
allow researchers and others to more accurately identify prevalence of disability and disability type, 
incidence of disability in our aging population, and distribution of disability and disability type 
regionally and between states.  
 
Priorities for the Division of Human Development and Disability (ordered chronologically): 
Priority 1:  Reduce disparity in obesity and other health indicators in children, youth and adults with 
disabilities. 
 
Priority 2:  Improve developmental outcomes of all children. 
 
Priority 3:  Ensure that all newborns are screened and assessed for hearing loss and receive appropriate 
intervention according to established guidelines.   
 
Priority 4:  Identify and reduce disparities in health care for persons with disabilities. 
 





By focusing on our goals and priorities, we intend to achieve the following outcomes: 
 
 Change personal health behaviors and risk factors (e.g., obesity, smoking) to improve health in 
children, youth and adults with disabilities.   
 Mediate the impact of poverty on developmental outcomes for young children. 
 Increase early identification and intervention for infants and young children with disabling conditions. 
 Improve health care access for children, youth and adults with disabilities. 
 Improve public health surveillance systems to track the health, development and participation of 
persons with disabilities across the life course. 
 
How We Developed Our Priorities 
 
DHDD’s reach is broad.  Its networks of EHDI programs in 53 states and territories ensures infant hearing 
screening for virtually all children born in the United States.  Our 16 Disability and Health state programs and 6 
NACCHO community sites provide public health outreach and access to persons with disabilities in many areas 
around the country.  Through implementation, evaluation and dissemination of evidence-based preventive 
health activities targeting people with disabilities, DHDD seeks to prevent the development of secondary 
conditions, address health disparities, and develop a stronger evidence base of effective preventive 
programming.  Our desire is to expand this network as the programs demonstrate their merit in coordinating 
essential public health services such as emergency preparedness and health care access.  DHDD also supports 
eight condition-specific public health practice and resource centers, such as the Christopher and Dana Reeve 
Foundation and Special Olympics International.  These resource centers have large national and global 
constituencies.  In our new DHDD Partnership initiative, they are working together on DHDD-specific goals 
such as obesity, as well as developing collaborations for shared public health concerns.  DHDD also works 
closely with national and international cross-disability and academic organizations to extend its reach and 
translate its research into programs.  
 
Surveillance and Research 
 
A particular focus of DHDD and the CDC Disability and Health Work Group is to address inclusion of disability 
in surveillance, programs and policies.  In order to ensure understanding of disability populations, disability 
status needs to be incorporated into surveillance tools in ways that it currently is not.  The ACA, in its language 
in Section 4302, confirms the need to address this deficit. Through its surveillance and public health research, 
DHDD has illustrated that people with disabilities incur higher rates of obesity, diabetes, preventable 
infections, sexual violence and mental health conditions such as depression than do the general population.  
Further, people with disabilities are over-represented in populations experiencing obesity, smoking and other 
chronic conditions, requiring us to translate best practices in ways that combat these behaviors by working 
closely with our counterparts in chronic disease and injury prevention programs.  In the next four years, DHDD 
is specifically addressing obesity in persons with disabilities as an exemplar of inclusion. 
 
Developing and Implementing Effective Interventions 
Working with the newly established CDC Disability and Health Work Group and with partners in states, DHDD 
is actively pursuing the inclusion of people with disabilities in public health programs and policies.  For 
example, obesity prevention and intervention programs need to plan for purposeful inclusion of persons in 
wheelchairs, with visual limitations, and intellectual disabilities.  In cases where inclusion of disability 
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populations are not effective, research is needed to provide policies, programs, and practices that are 
effective for our populations. 
 
Effectively communicating health information to our different audiences is critical to our ability to translate 
research to action.  For example, public awareness campaigns on health concerns, like the importance of 
mammograms for women with mobility limitations, have contributed to changing health behaviors among 
these women.  Similarly, conferences that bring together the perspectives of persons with disabilities, 
researchers, and professionals are important venues to ensure that proposed strategies and approaches are 
appropriate, credible and feasible.  Our website provides valuable information to multiple audiences and will 
soon be supplemented with information for each state on the health disparities of adults with disabilities. 
 
Ongoing activities in surveillance and research, program implementation, and communication and 
dissemination are the tools employed by our Division to effect change.  The overlap between these activities 
requires evaluating performance, investing in social capital and public health infrastructure, and translating 
knowledge gained into effective public health practices.  In addition to contributing to change through 
expanded diffusion of disability awareness into mainstream public health activities, inclusion is also a product 
of change, inextricably linked to successful outcomes DHDD seeks to effect change in areas such as public 
policy, employment, health care finance, technology, research, communication and education, and changes to 
the built environment.  Examples of outcomes supported by DHDD in which inclusion plays a key role: 
 
 Public policy:   providing evidence contributing to legislation that can improve the health and well-
being of people with disabilities, such as the Americans with Disabilities Act (ADA); 
 
 Employment:  providing knowledge of the impact of employment and disability on health, contributing 
to creative programs, such as the Ticket to Work and Work Incentives Act (TWWIA), that can improve 
health and maintain employment for people with disabilities; 
 
 Health care finance:  providing cost estimates for disability populations, such as persons with spina 
bifida or those with mobility limitations, to help plan for inclusion of disability populations into 
accountable care organizations (ACOs), a new health care delivery system in the ACA; 
 
 Technology:  providing evidence that supports the expanded use of electronic medical records and 
meaningful use in ways that assure improved outcomes, for example, among newborns and children 
screened for hearing loss; 
 
 Research:  inclusion of disability into developing specialized disability-specific measurement 
approaches such as disability adjusted quality of life indicators, use of waist circumferences as more 
accurate proxies for obesity, or positive parenting skills that contribute to improved developmental 
milestones in children as means to assure that outcomes can be more accurately measured; 
 
 Communication and education:  inclusion of approaches that incorporate Section 508 (a 1998 
amendment to the U.S. Rehabilitation Act of 1973), which assures that electronic and information 




 Changes to the built environment:  providing evidence of successful implementation of elements of 
universal design that allow access to health care for people with disabilities, reflected in Title III, 
Section 4203 of the ACA. 
 






Characterize the problem:   Prevalence, Incidence and Distribution 
 
Four Year Outcome:   Determine surveillance systems and monitor progress on specific health indicators of 
children, youth and adults with disabilities.   
 
Progress Indicators:  
1. Publish surveillance data that identifies prevalence of people with disabilities who are at greatest risk 
of obesity.   
2. Monitor status of HP2020 Disability and Health objectives and promote achievement of select 
objectives.   
3. Prioritize health indicators for intervention. 
 
 
Develop, Implement and Translate Feasible and Effective Interventions 
 
Four Year Outcome:   Reduce by 10% the disparity in obesity between children, youth and adults with mobility 
and intellectual limitations relative to persons without disabilities. 
 
Progress Indicators:   
1. Summarize and publish research on effectiveness of current generic obesity prevention/ intervention 
programs (including communication campaigns) to determine how program access and delivery may 
need to be modified for disability inclusion.  
2. Develop guidance for practitioners that focuses on methods for including people with disabilities in 
obesity prevention and intervention programs. 
3. In collaboration with the Division of Nutrition, Physical Activity and Obesity, Division of Adolescent and 
School Health and others, increase targeting of current population-based obesity prevention efforts to 
accommodate persons with disabilities. 
4. Expand capacity to implement state-based interventions related to health indicators of persons with 
disabilities.   
5. Engage in strategic collaboration with NCBDDD Public Health Resource and Information Centers to 
enhance educational materials for consumers and their families, and for health and public health 
personnel. 
Priority 1:  Reduce disparity in obesity and other health indicators in children, youth and 
adults with disabilities. 
 
Priority 1:  Ensure that all newborns are screened and assessed for hearing loss and 




6. Support demonstration projects and translation initiatives of effective interventions targeted at 
highest risk groups and those most likely to succeed. 
7. Implement effective targeted evidence-based interventions for obesity prevention/ intervention for 
children and adults with disabilities. 
8. Increase the number and quality of obesity prevention/intervention programs that are appropriate for 






Characterize the Problem:  Prevalence, Incidence and Distribution 
 
Four Year Outcome:  Develop, expand, and disseminate population-based estimates of prevalence, 
developmental outcomes and factors associated with developmental outcomes among children at 




1. Publish updated prevalence estimates, patterns of service utilization, and developmental outcomes 
among children at developmental risk. 
2. Conduct follow-up studies with children who have key conditions and identify factors associated with 
their developmental outcomes.   
3. Evaluate the utility of disability indicators in the National Survey of Children’s Health and the National 
Survey of Children with Special Health Care Needs relative to prevalence of disability, service 
utilization, and health and developmental outcomes. 
Four Year Outcome:  The health needs, service utilization, environments, and outcomes for children and youth 
with complex disabling conditions are characterized to facilitate transition and optimize development.   
Progress Indicators: 
1.  The DHDD life course conceptual model (based on the International Classification of Functioning) is recognized 
and applied in research and intervention for children and youth with complex disabling conditions to better 
facilitate transition from childhood to adulthood. 
2. Retrospective studies identify service utilization, outcomes and information gaps for persons with select 
conditions (e.g., muscular dystrophy). 
3. Collect and analyze standardized, longitudinal data on needs, service utilization, environmental factors and 
health and developmental outcomes for persons with select conditions (e.g., spina bifida, Fragile X). 
4. Release care guidelines for select complex disabling conditions and document that knowledge of care providers 
and service delivery has improved. 
5. NCBDDD Public Health Resource and Information Centers demonstrate the impact of educational materials for 
consumers and their families, and for health and public health personnel. 




Develop, Implement and Translate Feasible and Effective Interventions 
Four Year Outcome:  With the Administration for Children and Families (ACF) and other organizations, 
implement the Legacy for Children (LFC) parenting program in multiple sites to decrease the prevalence of 
intervention children falling below average on measures of intellectual functioning or demonstrating 
behavioral problems. 
Progress Indicators: 
1.  Collaborate with ACF on a feasibility study to develop, plan and adapt LFC for community implementation in 
selected ACF Early Head Start sites. 
2. Evaluate the feasibility of implementing LFC in selected ACF Early Head Start sites, evaluating the community 
context, participant-program match, program perceptions, participation patterns, goals attainment, and lessons 
learned (consistent with Early Head Start program demonstration evaluations).   
3. Leverage the Early Head Start system to ensure early identification and continuity of care for children enrolled in 
the intervention with suspected developmental delays. 
4. Adapt LFC curriculum by incorporating findings from the ACF Early Head Start feasibility study. 
5. Design a demonstration study to evaluate the effectiveness of the LFC program within Early Head Start-Legacy 
sites. 
6. Fund demonstration sites to assess the impacts of LFC on enrolled children relative to comparison children at 2 





Characterize the problem:   Prevalence, Incidence and Distribution 
 
Four Year Outcome:  Improve the quality and use of data to assure the following newborn hearing program 
objectives have been achieved in the reporting jurisdictions:  a) screening rate of 95% or more; b) audiology 
testing of 70% of infants failing hearing screening; and c) referral to early intervention services of 90% of 
infants with hearing loss. 
 
Progress Indicators:  
1.  Enhance state-based electronic case management for follow-up of infants. 
2. Expand capacity to validate and analyze data related to hearing screenings and audiology tests. 
3. Increase efforts to collect referral data to early intervention and other services.  
4. Adopt health information technologies common to multiple child health information systems to assist 
in follow-up activities and collection of data. 
 
Four Year Outcome:  Validated metrics are established to measure appropriateness for referral and 
intervention success for infants with hearing loss. 
 
  
Priority 3:  Ensure that all newborns are screened and assessed for hearing loss and receive 




1. Support a feasibility study in a limited number of states to develop data management systems capable 
of collecting and reporting developmental outcomes of infants/children identified through the hearing 
screening programs.  





Characterize the problem:   Prevalence, Incidence and Distribution 
 
Four Year Outcome:  Unmet health care need of persons with disabilities is monitored and reported regularly 
to advance health care access. 
 
1. Develop and publish regular reports on unmet health care needs generally and on targeted topic reports 
through Vital Signs, MMWR or other avenues. 
2. In collaboration with partners and others, disseminate information on health care access. 
 




1. Determine a feasible definition of intellectual disability for surveillance purposes. 
2. Collaborate with international initiatives to refine definitions and approaches to assess health status 
and health needs of persons with intellectual disabilities. 
3. In collaboration with other federal agencies and national organizations, identify available data and data 
needs on populations of adults with intellectual disabilities. 
4. Support and evaluate pilot studies on catchment-area surveillance of health status and health needs of persons 
with intellectual disabilities. 
 
 
Develop, Implement and Translate Feasible and Effective Interventions 
 
Four Year Outcome:  States use disability disparity data to prioritize their public health policies and programs 




1. Analyze state-level BRFSS data to compare people with disabilities to those without disabilities for 
approximately 65 health care and health behavior indicators. 
2. Create an interactive, web-based platform to display results; provide technical assistance to states 
using the reporting system; work with state partners, researchers, and others to develop and identify 
user-based needs and preferences.  
3. Enhance BRFSS data with NHIS and NHANES data to confirm health disparities by disability status and 
identify disparities by type of disability. 
Priority 4:  Identify and reduce disparities in health care for persons with disabilities. 
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4. Enhance use of the data reporting system through follow-up and technical assistance. 
5. Collaborate with Division of Adolescent and School Health (CDC), Maternal and Child Health, 
Department of Education, and others to coordinate state priorities and planning on care for children, 
youth, and adults with disabilities and special health care needs.   
6. Document impact of data availability on state and national programs and policies in awareness of 
health disparities of people with disabilities. 
 
Four Year Outcome:  Reduced proportion of people with disabilities who report delays in receiving primary 
and periodic preventive care due to specific barriers (HP 2020 Developmental Objective 4). 
 
Progress Indicators: 
1. Promote inclusion of people with disabilities in CDC-funded programs and policies, particularly those 
focused on primary and preventive care. 
2. Maintain and expand efforts by State D&H programs to conduct health promotion activities to include: 
a) public awareness campaigns on obesity, physical activity, and smoking, preventive services (e.g., The 
Right to Know Campaign); b) state and local training on health promotion (including accessibility) for 
providers and people with disabilities; and c) accessibility assessments of health care facilities. 
3. Assure that State D&H programs apply an inclusion approach to targeted public health campaigns 
/interventions (e.g., accessible medical equipment, diabetes, obesity, emergency preparedness, etc.).  
4. Expand capacity to implement state-based interventions related to health care access for persons with 
disabilities. 
5. Assure adequate technical support for State D&H programs to conduct these campaigns, trainings and 
assessments. 
6. Incorporate a policy requirement for inclusion of people with disabilities into health promotion 
campaigns in State D&H FOAs. 
7. Engage in strategic collaboration with NCBDDD Public Health Resource and Information Centers to 
promote access to primary and periodic preventive care.  
8. With other agencies, build capacity to analyze health services data and have those analyses inform 
policies to improve health care access. 
 
 
Characterize the Problem:  Prevalence, Incidence and Distribution 
 










1. Document the effects of the CDC Disability and Health Workgroup on incorporating disability status as 
a demographic variable into all current and future CDC surveys by resolving differences among 
disability identifier questions or incorporating the definition recommended as a result of the ACA.    
2. Develop and demonstrate validity of standard disability identifiers. 
3. Coordinate efforts to modify identified surveillance system units to include disability status as 
demographic variable in all relevant surveys in CDC. 
Four Year Outcome:  Disability status is included in all CDC reports on health disparities as a means of 
documenting possible disparities. 
 
Progress Indicators: 
1. Provide information and data for inclusion of disability-related disparities in OSELS annual disparities 
report.  
2. Contribute to documenting health disparities experienced by people with disabilities. 
3. Contribute to inter-agency planning on implementation of Affordable Care Act and related health care 
reform. 
Four Year Outcome:  Increased awareness of disability and health across CDC. 
 
Progress Indicators: 
1. Document the effects of the CDC Disability and Health Workgroup in recognizing and communicating 
best practices in disability and health.  
2. Identify agency best practices and showcase those programs across CDC by establishing a web 
presence to spotlight successful programs. 
Four Year Outcome: Increase to 90% inclusion of disability in CDC programs and policies, including FOAs and 
accessibility of printed and electronic materials. 
 
Progress Indicators: 
1. Document the effects of the CDC Disability and Health Workgroup in influencing and implementing 
policies in incorporating people with disabilities into relevant CDC programs and policies by examining 
opportunities for disability inclusion in programs and policies, including FOAs (current and future) and 
accessibility of printed and electronic materials.  
2. Assure that identified CDC programs include disability in relevant programs and policies, including 
FOAs and accessibility of printed and electronic materials. 
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Acronym List – Appendix I 
 
A 
AAP – American Academy of Pediatrics 
ACA – Affordable Care Act 
ACD – Alveolar Capillary Dysplasia 
ACF – Agency for Children and Families 
ACO – Accountable Care Organization 
ADDM – Autism and Developmental Disabilities Monitoring Network 
ADHD – Attention Deficit Hyperactivity Disorder 
AHRQ – Agency for Healthcare Research and Quality 
ASD – Autism Spectrum Disorder 
 
B 
BRFSS – Behavioral Risk Factor Surveillance System 
 
C 
CADDRE – Center for Autism and Developmental Disabilities Research and Epidemiology 
CBDRP – Centers for Birth Defects Research and Prevention 
CDR Paralysis Resource Center – Christopher and Dana Reeve Paralysis Resource Center 
CMV – Cytomegalovirus 
 
D 
DBA – Diamond Blackfan Anemia 
DBD – Division of Blood Disorders 
DBDDD – Division of Birth Defects and Developmental Disabilities 
DDT – Division of Diabetes Translation 
D&H – Disability and Health 
DHDD – Division of Human Development and Disability 
DHDSP – Division of Heart Disease and Stroke Prevention 
DHQP – Division of Healthcare Quality Promotion 
DNPAO – Division of Nutrition, Physical Activity and Obesity 
DRH – Division of Reproductive Health 
DVT – Deep Vein Thrombosis 
 
E 
EHDI – Early Hearing Detection and Intervention Program 
EHR – Electronic Health Record 
 
F 
FAS – Fetal Alcohol Syndrome 
FASD – Fetal Alcohol Spectrum Disorder 
FDA – Food and Drug Administration 
FOA – Funding Opportunity Announcement 
 
G 





HP 2020 – Healthy People 2020 
HRSA – Health Resources and Services Administration 
HTC – Hemophilia Treatment Center 
 
I 
IHS – Indian Health Service 
IMMPCt – International Micronutrient Malnutrition Prevention and Control Program 
IOM – Institute of Medicine 





KABs – Knowledge, Attitudes and Beliefs 
 
L 
LFC – Legacy for Children 
LTSAE – Learn the Signs. Act Early 
 
M 
MADDSP – Metropolitan Atlanta Developmental Disabilities Surveillance Program 
 
N 
NBDPN- National Birth Defects Prevention Network 
NBDPS – National Birth Defects Prevention Study 
NBS – Newborn screening 
NCBDDD – National Center on Birth Defects and Developmental Disabilities 
NCCDPHP – National Center for Chronic Disease Prevention and Health Promotion 
NCHS – National Center for Health Statistics 
NCIPC – National Center for Injury Prevention and Control 
NHANES – National Health and Nutrition Examination Survey 
NHIS – National Health Interview Survey 
NHLBI – National Heart, Lung, and Blood Institute 
NIAAA – National Institute of Alcohol Abuse and Alcoholism 
NINDS – National Institute of Neurological Disorders and Stroke 
NSFG – National Survey of Family Growth 
NTD – Neural Tube Defect 
 
O 
OD – Office of the Director 








PE – Pulmonary Embolism 
PWD – Persons with Disabilities 





RuSH – Registry and Surveillance System for Hemoglobinophathies 
 
S 
SCD – Sickle Cell Disease 
SEED – Study to Explore Early Development 
SSRI – Selective Serotonin Reuptake Inhibitors 
 
T 
TWWIA – Ticket to Work and Work Incentives Act 
 
U 
UDC – Universal Data Collection 
 
V 
VWD – Von Willebrand Disease 
 
W 
WHO – World Health Organization 




























Detail of Personnel 214 42 USC Sec. 215 Authorizes CDC, through HHS, to detail officers or 
employees to other departments or workplaces to 
cooperate in, or conduct work related to, the functions of 
HHS & CDC. 
Public Health Research 
& Investigations 
301 42 USC Sec. 241 General authority for public health research and 
investigations. 
Research, Evaluation, & 
Demonstrations 
304 42 USC Sec. 242b General authority for research, evaluations, and 
demonstrations in health statistics, health services, and 
health care technology assessment. 
International 
Cooperation 
307 42 USC Sec. 242l General authority for CDC to cooperate and collaborate 
with governments in other nations. 
Confidentiality in data 
collection 
308d 42 USC Sec. 242k Provides for the protection of confidential data collected 
under selected surveys conducted under the authority of 
Sections 304, 306, and 307 of the Public Health Service 
Act. 
Health Conferences and 
Publication of Health 
Education Materials- 
310 42 USC Sec. 242o Provides general authority for conferences of state health 
authorities, and to publish health education and 
information materials. 
Cooperation with State 
& local health 
departments 
311 42 USC Sec. 243 Provides general authority for cooperation with State and 
local health authorities.  
Grant Authority for 
Preventive Health 
Services 
317 42 USC Sec. 247b Provides authority for CDC to make grants to State and 
local health authorities for preventive health services. 
Public Health 
Emergencies 
319 42 USC Sec. 247d Provides authority for the HHS Secretary to declare and 
respond to public health emergencies.  
Buildings & Facilities 319D 42 USC Sec. 
247d-4 
Provides authority for CDC facility and capacity 
expansion, and includes multi-year contract authority to 
expand training of personnel, improve communications 
facilities, networks and improve capabilities for public 












327 42 USC Sec. 254 Preserves authority for the Secretary to furnish any 
materials, supplies, or equipment, or perform any 
services requested by another federal department, or to 
request materials, supplies, or equipment from another 
federal department. 
Preparation of Biological 
Products 
352 42 USC Sec. 263 Provides authority for CDC to prepare biological products 
for its own use or for the use of other agencies, public or 
private organizations, or individuals engaged in medical 
work with such product is not available by another 
licensed source. 
CDC Foundation 399G 42 USC Sec. 
280e-11 
Provides authority for the establishment of the CDC 
Foundation and the endowed programs managed by the 
Foundation. 
Research Project Grants 
and Contracts 
1102 42 USC Sec. 
300b-1 
Authorizes CDC to conduct and support research and 
grants for the study of genetic diseases and hemophilic 
conditions. 
Technology Transfer   15 USC Sec. 3710 Authorizes CDC, through HHS, to transfer federally owned 
or originated technology to state and local governments 
and the private sector.  
Bayh-Dole Act of 1980, 
P.L. 96-517 
P.L. 96-517 35 USC Sec. 200-
212 
Allows for the transfer of exclusive control over 
government funded inventions to universities and 
businesses operating with federal contracts for the 
purpose of further development and commercialization.  











and general authority 
317C 42 USC Sec. 
247b–4 
Provides for the establishment of the National Center on 
Birth Defects and Developmental Disabilities. 
Folic Acid 317J 42 USC Sec. 
247b–11 
Authorizes CDC to conduct programs – education, 
training, research, and epidemiological studies – to 




317Q 42 USC Sec. 
300b-7 
Authorizes CDC to conduct and support research and 
grants for the study of Muscular Dystrophy. 
Establishment of Fetal 
Alcohol Syndrome 
Prevention and Services 
Program  
399H - K 42 USC Sec. 280f Authorizes the establishment of a comprehensive Fetal 
Alcohol Syndrome and Fetal Alcohol Effect prevention, 
intervention and services delivery program. 
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Hearing Loss in Infants 
399M(b) 42 USC Sec. 
280g-1 
Establishes the National Center on Birth Defects and 
Developmental Disabilities (NCBDDD), and provides 
authority for CDC programs in surveillance, applied 
research, and education related to birth defects; folic 
acid; cerebral palsy; mental retardation; child 
development; newborn screening; autism; fragile X 
syndrome; fetal alcohol syndrome; pediatric genetic 
disorders and disability prevention.  This section also 
provides specific authority for the Spina Bifida Program. 
Congenital Heart 
Futures Act (passed in 
2010 as part of Health 
Reform) 
399 V-2 42 U.S.C. 241 et 
seq 
Provides authority for CDC to (1) conduct (or provide 
grants to State and local authorities to conduct) research, 
education and training, technical assistance, and 
evaluation for folic acid prevention of birth defects and 
(2) to facilitate further research into the types of health 
services patients use and to identify possible areas for 
educational outreach and prevention. 
Developmental 
Disabilities Surveillance 
and Research Programs 
399AA 42 USC Sec. 280i Establishes medical professional, community, social 
services and youth education programs focused on the 
effects of fetal alcohol syndrome, as well as a prevention 
and diagnosis program.  Authorizes the Secretary to make 
grants to the above programs, and creates a National 
Task Force to foster coordination between such 
programs.  
Combating Autism Act:  
Authorization of 
Appropriations 
399EE 42 USC 280i–4 Provides for authorized appropriations to conduct the 
activities described in 399AA and 399BB. 
Tourette Syndrome 1108 42 USC Sec. 
247b-11 
Provides authority for CDC to conduct (or provide grants 
to State and local authorities to conduct) research, 
education and training, technical assistance, and 
evaluation for folic acid prevention of birth defects. 
NCBDDD Shared Authorities 
  






Research Relating to 
Preterm Labor and 
Delivery and the Care, 
Treatment and 
Outcomes of Preterm 
301 42 USC 247b–4f Provides for the expansion, intensification, and 
Coordination of the activities of the Centers for Disease 
Control and Prevention with respect to preterm labor and 
delivery and infant mortality. 
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and Low Birth Weight 
Infants 







Coordinating Council on 
Prematurity and Low 
Birth weight 
399Q 42 USC 247b–4g Provides authority to stimulate multidisciplinary research, 
scientific exchange, and collaboration among the 
agencies of the Department of Health and Human 
Services and to assist the Department in targeting efforts 
to achieve the greatest advances toward the goal of 
reducing prematurity and low birth weight. 
Support for Patients 
Receiving a Positive 
Diagnosis of Down 
Syndrome or Other 
Prenatally or Postnatally 
Diagnosed Conditions  
399R 42 U.S.C. 280g 
et seq 
Provides authority to increase the provision of 
scientifically sound information and support services to 
patients receiving a positive test diagnosis for Down 
syndrome or other prenatal and postnatal diagnosed 
conditions. 
Autism Education, Early 
Detection and 
Intervention 
399BB 42 USC Sec. 
280i-1 
Provides authority for CDC to conduct research, make 
grants or cooperative agreements, and provide technical 




Newborn and Child 
Screening Programs 
1110 42 U.S.C. 300b-9 Provides for authorized appropriations from FY09 – FY12. 
Interagency 
Coordinating Committee 
on Newborn and Child 
Screening 
1114 42 USC 300b-13 Provides for the establishment of an Interagency 
Coordinating Committee on Newborn and Child Screening 
to: 
(1) assess existing activities and infrastructure, including 
activities on birth defects and developmental disabilities 
authorized under section 317C, in order to make 
recommendations for programs to collect, analyze, and 
make available data on the heritable disorders 
recommended by the Advisory Committee on Heritable 
Disorders in Newborns and Children under section 1111, 
including data on the incidence and prevalence of, as well 
as poor health outcomes resulting from, such disorders; 
and 
(2) make recommendations for the establishment of 
regional centers for the conduct of applied 
epidemiological research on effective interventions to 
promote the prevention of poor health outcomes 
resulting from such disorders as well as providing 




Stakeholders and Stakeholder Groups Providing Input in NCBDDD Strategic Plan 
Appendix III 
Gaining Input from Key Informants and Partner Stakeholder Groups: 
 
Two strategies were used to gain input from partners.  Key informants (e.g., cross-cutting experts in science, 
program and policy) were interviewed during one hour telephone or face-to-face meetings.  NCBDDD leaders 
– the Acting Director, Deputy Director, Division Directors and senior subject matter experts - conducted these 
interviews.   A standard series of questions were used and interview notes were carefully taken, sorted, and 
considered by program staff as the strategic plan was revised.     
 
The second partner input strategy utilized a webinar format to gain input from a large group of constituent 
groups.  Two webinars were held to inform and gain input from the Friends of NCBDDD and major partners.  
The first webinar described the rationale for creating the plan and laid out draft priorities and intended 
outcomes.  The second webinar centered on identifying the Center and Division goals and priorities, as well as 
the intended outcomes that would be achieved through these activities.  Particular attention was paid to 
explaining NCBDDD’s underlying rationale behind the goals and priorities outlined in the plan and offering 
partners an opportunity to ask questions aimed at clarifying the plan’s content.  Partner input was carefully 
catalogued and considered for incorporation into the final strategic plan.   
 
Partner Stakeholder Groups Included: 
Academy for Educational Development 
Alaska Native Tribal Health Consortium 
Alpha-1 Foundation 
American Academy of Audiology 
American Academy of Family Physicians 
American Academy of Orthopedic Surgeons (AAOS) 
American Academy of Otolaryngology 
American Academy of Pediatrics (AAP) 
American Academy of Physical Medicine and Rehabilitation 
American Academy of Physician Assistants 
American Association of People with Disabilities (AAPD) 
American Association of Poison Control Centers 
American Association of Retired People (AARP) 
American Association on Health Disability (AAHD) 
American Association on Mental Retardation (AAMR) 
American Baby Group 
American College of Medical Genetics 
American College of Nurse Practitioners 
American College of Obstetricians and Gynecologists (ACOG) 
American College of Physicians 
American College of Preventive Medicine (ACPM) 
American Diabetes Association 
American Foundation for the Blind (AFB) 
American Heart Association 
American Medical Association (AMA) 
American Occupational Therapy Association 
American Psychological Association 
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American Public Health Association (APHA) 
American School Health Association (ASHA) 
American Society of Hematology (ASH) 
American Society of Human Genetics 
American Society of Pediatric Hematologists and Oncologists (ASPHO) 
American Speech-Language-Hearing Association (ASHA) 
American Therapeutic Recreation Association (ATRA) 
American Thrombosis and Hemostasis Network 
Amputee Coalition of America (ACA) 
Arc of Georgia 
Arc of the United States 
Arthritis Foundation 
Association for Prevention, Teaching and Research 
Alexander Graham Bell Association for the Deaf and Hard of Hearing 
Association of Maternal and Child Health Programs (AMCHP) 
Association of Programs for Rural Independent Living (APRIL) 
Association of Public Health Laboratories (APHL) 
Association of State and Territorial Health Officials (ASTHO) 
Association of Teachers of Maternal and Child Health (ATMCH) 
Association of University Centers on Disabilities (AUCD) 
Association of Women's Health, Obstetric and Neonatal Nurses 
Asthma and Allergy Foundation of America 
Atlanta Alliance on Developmental Disabilities (AADD) 
Atlanta City Schools 
Autism Coalition 
Autism Science Foundation 
Autism Society of America    
Autism Society of America (ASA) 
Autism Speaks 
Backus Children's Hospital 
Brain Injury Association of America 
Brigham and Women's Hospital 
Bristol-Myers Squibb 
Bubel/Aiken Foundation 
Buford City Schools 
Business Edge 
C.S. Mott Center for Human Growth and Development 
California State University 
Canadian Institute of Child Health 
Case Western Reserve University 
Catalina Health Resource 
Catholic University of America 
Cavarocchi - Ruscio - Dennis (CRD) Associates 
CDC Foundation 
Center for Assistive Technology and Environmental Access 
Center for Child Health Improvement (CHI), The 
Center for Development and Disability 
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Center for Disability Policy & Research 
Center for Health and Healthcare in Schools 
Center for Health Improvement 
Center for Health Services Research and Policy 
Center for Population Research, NICHD, NIH 
Center for Rehabilitation Technology 
Center for Science in the Public Interest 
Child Care Bureau, HHS 
Child Neurology 
Child Study Center 
Child Trends, Inc 
Children and Adults with Attention Deficit/Hyperactivity Disorder (CHADD) 
Children's Habilitation Center 
Children's Healthcare of Atlanta 
Children's Medical Service - Clayton  
Christopher and Dana Reeve Foundation 
Christopher Reeve Paralysis Foundation 
Citizens United for Research in Epilepsy (CURE) 
CityMatCH at University of Nebraska Medical Center 
Clayton County Schools 
Cobb County Schools 
Coleman Institute for Cognitive Disabilities 
Commonwealth Fund 
Conceive Magazine 
Conquer Fragile X 
Cooley's Anemia Foundation (CAF) 
Council of State and Territorial Epidemiologists (CSTE) 
Covering Kids & Families 
Cystic Fibrosis Foundation 
Dan Marino Foundation 
Daniella Maria Arturi Foundation 
David Geffen School of Medicine at the University of California  
Decatur City Schools 
Dekalb County Board of Health 
Dekalb County Schools 
Department of Human Genetics, Emory University School of Medicine 
Department of Human Services State of New Jersey 
Department of Veterans Affairs 
Diamond Blackfan Anemia Foundation 
Diamond Blackfan Anemia Registry 
Disability Policy Collaborative 
Down Syndrome Research and Treatment Foundation 
Dupont Hospital for Children 
Easter Seals, Inc. 
EDC Health & Human Development Programs 
eHealth Forum 
Emory Autism Resource Center 
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Emory Children's Center 
Emory Clinic 
Emory University School of Medicine 
Exceptional Parent Magazine/EP Global 
Family to Family for Health Choices/Parent to Parent of Georgia 
Family Voices 
FAS Family Resource Institute 
First Signs (Autism Group) 
Florida Department of Health 
Fragile X Research Foundation (FRAXA) 
Fulton County Dept. Health and Wellness 
Fulton County Schools 
GA DHR 
Genetic Alliance, Inc. 
Georgia Department of Education 
Georgia SIDS Project 
Georgia State University 
Grady Health System 
Gruma, SA 
Gwinnett County Public Schools 
Hands and Voices 
Health Resources and Services Administration 
Helen Keller Foundation for Research and Education 
Helen Keller National Center for Deaf-Blind Youths and Adults 
Hemophilia and Thrombosis Research Society 
Hemophilia Federation of America  
Hereditary Hemorrhagic Telangiectasia Foundation Intenational 
Hope and Light Foundation 
Hunter's Hope Foundation 
Inova Fairfax Hospital 
International Society of Thrombosis and Hemostasis 
Iron Disorders Institute 
Lakeshore Foundation 
Learning Disabilities Association of America 
M.I.N.D. Institute 
M.I.S.S. Foundation 
March of Dimes 
March of Dimes Birth Defects Foundation 
Maria Arturi Foundation 
Marietta City Schools 
Marion Downs Hearing Center 
MCHB Leadership Education in Adolescent Health (LEAH) Program 
Meharry Medical College 
Michigan State University 
Morehouse School of Medicine 
Mt. Sinai Center for Children's Environmental Health and Disease Prevention Research 
Muscular Dystrophy Association 
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Muscular Dystrophy Family Foundation 
National Alliance for Autism Research (NAAR) 
National Alliance for Hispanic Health 
National Alliance for the Mentally Ill 
National Alliance for Thrombosis and Thrombophilia 
National Association for the Education of Young Children 
National Association of Children's Hospitals 
National Association of Children's Hospitals and Related Organizations 
National Association of County and City Health Officials (NACCHO) 
National Association of Development Disabilities Councils 
National Association of Hispanic Nurses 
National Association of Nurse Practitioners in Women's Health 
National Association of Pediatric Nurse Associates & Practitioners (NAPNAP) 
National Association of School Psychologists 
National Association of State Head Injury Administrators 
National Autism Association 
National Birth Defects Prevention Network (NBDPN) 
National Black Nurses Association 
National Center for Gender Issues and Attention Deficit/Hyperactivity Disorder  
National Center on Physical Activity 
National Council of La Raza 
National Council on Disability 
National Council on Folic Acid 
National Down Syndrome Society 
National Foundation for Facial Reconstruction 
National Fragile X Foundation 
National Healthy Mothers, Healthy Babies Coalition 
National Hemophilia Foundation (NHF) 
National Hispanic Medical Association 
National Institute on Alcohol Abuse and Alcoholism 
National Marfan Foundation 
National Medical Association 
National Multiple Sclerosis Society 
National Organization on Disability (NOD) 
National Organization on Fetal Alcohol Syndrome 
National Perinatal Association 
New Jersey Medical School 
Northside Hospital Perinatal Loss Offices 
Oral Health America 
Organization for Autism Research (OAR) 
Organization of Teratology Information Services 
Pan American Health Organization (PAHO) 
Parent Project Muscular Dystrophy (PPMD) 
Parents of Infants and Children with Kernicterus 
Partnership for Prevention 
Philadelphia College of Ostepathic Medicine 
Reaching for the Stars 
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Research and Training Center for Children's Mental Health 
Research and Training Center on Independent Living 
Research and Training Center on Rural Disability 
Research Autism 
Research!America 
Robert Wood Johnson Foundation 
Rollins School of Public Health, Emory University 
Saint Louis Arc 
Saint Louis University School of Medicine 
SHARE Atlanta: Pregnancy and Newborn 
Shepherd Center 
Sickle Cell Disease Association of America, Inc. (SCDAA) 
SMA Foundation 
Special Olympics 
Spina Bifida Association of America 
State Adolescent Health Coordinators Network 
Teratology Society 
The Arc of Georgia 
The Arc of the United States 
The Joey Company 
The Marcus Institute 
The NPD Group Inc. 
The What to Expect Foundation 
Tourette Syndrome Association 
Trisomy 18 Foundation 
Trust for America's Health 
Tuberous Sclerosis Alliance 
United Cerebral Palsy Associations (UCPA) 
United Cerebral Palsy Research and Educational Foundation 
University of Arizona 
University of Georgia 
University of Illinois at Chicago 
University of Maryland 
University of Miami 
University of Missouri-Columbia 
University of Nevada School of Medicine 
University of Oklahoma Health Sciences Center 
University of Texas School of Public Health, The 
University of Virginia 
University of Washington FAS Diagnostic Clinic 
Unlocking Autism 
USF College of Public Health 
Yale School of Medicine and School of Nursing 





Overview of Major Birth Defects 
Appendix IV 
 
Major birth defects are abnormalities that can affect the structure or function of an organ.  In the United 
States, major birth defects affect an estimated 3% of live births and they are the leading cause of infant death.  
There are more than 4,000 different known birth defects, ranging from minor to profound.   
 
Birth defects develop during pregnancy, and most occur during the first three months of gestation.  They may 
be caused by genetic, environmental or unknown factors.  In many cases, the cause is thought to be an 
interaction of genetic and environmental factors.   
 
Many experts classify birth defects into major categories:  structural or metabolic defects, and defects caused 
by congenital infections.  The most common example of a structural birth defect is congenital heart disease.  
Heart defects account for about one-third to one-quarter of all birth defects, accounting for one case per 100 
– 200 births.  Neural tube defects (spina bifida and anencephaly) are also structural defects, as are orofacial 
clefts (cleft lip, cleft palate, and combinations of the two).   
 
Congenital infections may also cause birth defects, and rubella (German measles) and cytomegalovirus (CMV) 
are well known causes.  Congenital rubella caries the highest risk for birth defects (about 20%), but because of 
universal immunization in the United States, it is now rarely seen.  CMV is probably the most common 
congenital infection and is associated with intellectual disability and hearing loss.   
 
Detailed case definitions exist for individual major birth defects, and in clinical practice, these defects are 
documented using the World Health Organization’s International Classification of Diseases, 9th Revision, 
Clinical Modification. 
 
In the United States, birth defects have accounted for over 139,000 hospital stays during a single year, 
resulting in $2.6 billion in hospital costs alone. 
 
 
